Short answer
USANA HEALTH SCIENCES INC (USNA) filed its Q4 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Oct 3, 2026. Quarterly revenue was $206M (down 3.6% year over year) with net income of −$6M.
Q4 2026 key financials · XBRL
- Revenue
- $206M
- −3.6% YoY · −7.8% QoQ
- Net income
- −$6M
- +14.8% YoY · +74.0% QoQ
- Operating margin
- -0.7%
- Gross margin
- 76.3%
- EPS (diluted)
- −$0.30
- +11.8% YoY · +74.1% QoQ
Source: XBRL data from the USANA HEALTH SCIENCES INC (USNA) Q4 2026 10-Q on SEC EDGAR. USD.
USANA HEALTH SCIENCES INC Q4 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $205.9M, down 3.6% YoY from $213.7M
- Consolidated gross margin 76.3% vs 77.2% YoY, operating margin (0.7%) vs 0.6%
- Best segment: Hiya revenue $31.5M, up 2.3%; worst: Rise revenue $3.6M, down 44.8%
- Cash $178.9M vs $158.4M, operating cash flow $45.0M, financing outflows $17.8M
- Headwinds: active Customers down 8.2%, challenging customer acquisition, Hiya digital marketing pressure in early 2026
Risk Factors
- No explicit 10-Q risk-factor changes disclosed, limiting assessment of newly added risks
- Hiya impairment risk: lower-than-expected performance and forecast changes triggered a $29,137 goodwill charge
- Credit covenant risk: amended minimum EBITDA threshold reduced to $70,000 when revolving exposure stays below $50,000
- Near-term operating risk: Hiya and Rise generated operating losses of $6,336 and $2,055 in the third quarter
- Foreign-exchange risk: 2026 net-investment hedge carried a $61,766 notional amount
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other USANA HEALTH SCIENCES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.